BioStock: Database lock in RhoVac’s phase IIb study

RhoVac is nearing data readout in the phase IIb study BRaVac with the drug candidate Onilcamotide. The company recently achieved database lock in the study, which means that the time has come to analyse the collected data. The topline results of the study are expected to be announced by early June.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/database-lock-in-rhovacs-phase-iib-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se